Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Eccles

Showing results (211-220 of 340) with videos related to

Pageof 34
Sort By:
BMJ Oncology|March 6, 2025
Long-term outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancerHend Hassan, Tameera Rahman, Andrew Bacon, et al.
The Journal of Pathology. Clinical Research|February 6, 2020
Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriersAlan D McCrorie, Susannah Ashfield, Aislinn Begley, et al.
The Journal of Pathology. Clinical Research|May 2, 2019
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)Kate Packwood, Guy Martland, Matthew Sommerlad, et al.
Eclinicalmedicine|April 23, 2019
Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast CancerD G Evans, S Thomas, J Caunt, et al.
Iscience|February 5, 2026
PFOS and PFOA exposure induces liver injury and sex-dependent immune effects in C57BL/6 miceAmélie Blais, Allison Loan, Eunnara Cho, et al.
BJC Reports|June 3, 2026
Contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM pathogenic variant carriers in two large cohort studiesIsaac Allen, Nancy Whish, Siddhartha Yadav, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 4, 2017
RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast CancerAnthony Howell, Linda Ashcroft, Lesley Fallowfield, et al.
Molecular Genetics & Genomic Medicine|June 2, 2015
Quantifying the cumulative effect of low-penetrance genetic variants on breast cancer riskConor Smyth, Iva Špakulová, Owen Cotton-Barratt, et al.
American Journal of Human Genetics|August 4, 2018
A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian CancerD Gareth R Evans, Elke M van Veen, Helen J Byers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening scheduleAdam N Rosenthal, Lindsay Fraser, Ranjit Manchanda, et al.
Pageof 34

Showing results (211-220 of 340) with videos related to

Sort By:
Pageof 34
BMJ Oncology|March 6, 2025
Long-term outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancerHend Hassan, Tameera Rahman, Andrew Bacon, et al.
The Journal of Pathology. Clinical Research|February 6, 2020
Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriersAlan D McCrorie, Susannah Ashfield, Aislinn Begley, et al.
The Journal of Pathology. Clinical Research|May 2, 2019
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)Kate Packwood, Guy Martland, Matthew Sommerlad, et al.
Eclinicalmedicine|April 23, 2019
Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast CancerD G Evans, S Thomas, J Caunt, et al.
Iscience|February 5, 2026
PFOS and PFOA exposure induces liver injury and sex-dependent immune effects in C57BL/6 miceAmélie Blais, Allison Loan, Eunnara Cho, et al.
BJC Reports|June 3, 2026
Contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM pathogenic variant carriers in two large cohort studiesIsaac Allen, Nancy Whish, Siddhartha Yadav, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 4, 2017
RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast CancerAnthony Howell, Linda Ashcroft, Lesley Fallowfield, et al.
Molecular Genetics & Genomic Medicine|June 2, 2015
Quantifying the cumulative effect of low-penetrance genetic variants on breast cancer riskConor Smyth, Iva Špakulová, Owen Cotton-Barratt, et al.
American Journal of Human Genetics|August 4, 2018
A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian CancerD Gareth R Evans, Elke M van Veen, Helen J Byers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening scheduleAdam N Rosenthal, Lindsay Fraser, Ranjit Manchanda, et al.
Pageof 34